Registered title, quoted from ClinicalTrials.gov
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06122389, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Histologically confirmed T-cell lymphoma;
Inclusion criterion 2
Female subjects with a possibility of becoming pregnant must undergo a blood pregnancy test prior to the first dose, with a negative result, and be willing to use a highly effective method of contraception for 90 days after signing the notification until the last dose of the study drug. Male subjects whose partners are women at risk of becoming pregnant should be surgically sterilized or agree to use highly effective methods of contraception for 90 days from the date of signing the notification until the last administration of the study drug;
Inclusion criterion 11
Received autologous stem cell transplantation within 60 days before signing the agreement, and received allogeneic stem cell transplantation within 90 days;
Exclusion criterion 3
Received anti-tumor treatment within 4 weeks before the first dose of the study drug, and received Chinese medicine treatment with anti-tumor effect within 2 weeks before the first dose of the study drug; Receiving steroid hormones within 7 days prior to the first dose of study drug administration;
Exclusion criterion 5
Have other malignancies within 5 years prior to screening, other than adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery (allowing hormone therapy for non-metastatic prostate cancer or breast cancer), and papillary thyroid cancer;
Exclusion criterion 12
ECOG physical status must be 0 or 1;
Inclusion criterion 3
Active phase of HBV or HCV infection;
Exclusion criterion 6
A history of immunodeficiency, including HIV seropositive, or other acquired or congenital immunodeficiency diseases;
Exclusion criterion 7
Pregnant and lactating women;
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06122389, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18-70 years old (including 18 and 70 years old), gender is not limited;
- Histologically confirmed T-cell lymphoma;
- ECOG physical status must be 0 or 1;
- Life expectancy ≥12 weeks;
- For relapsed refractory patients who have received ≥ first-line treatment, at least one prior treatment is adequate;
- Have not received histone deacetylase inhibitors;
- Have measurable lesions;
- Bone marrow function is basically normal;
- Liver and kidney function is basically normal;
- Blood coagulation function is basically normal;
- Female subjects with a possibility of becoming pregnant must undergo a blood pregnancy test prior to the first dose, with a negative result, and be willing to use a highly effective method of contraception for 90 days after signing the notification until the last dose of the study drug. Male subjects whose partners are women at risk of becoming pregnant should be surgically sterilized or agree to use highly effective methods of contraception for 90 days from the date of signing the notification until the last administration of the study drug;
- The subject has recovered from the toxic effects of the last treatment before the first dosing;
- The subject personally signs and dates the informed consent to show that the subject has been fully informed of all the circumstances related to the clinical trial;
- Subjects are willing and able to comply with visit schedules, dosing schedules, laboratory examinations, and other clinical trial procedures.
Exclusion Criteria:
- Have been treated with compounds with the same mechanism;
- Accompanied by central nervous system infiltration;
- Received autologous stem cell transplantation within 60 days before signing the agreement, and received allogeneic stem cell transplantation within 90 days;
- Major surgery or severe trauma occurred 4 weeks before the first dose of study drug administration;
- Received anti-tumor treatment within 4 weeks before the first dose of the study drug, and received Chinese medicine treatment with anti-tumor effect within 2 weeks before the first dose of the study drug; Receiving steroid hormones within 7 days prior to the first dose of study drug administration;
- Active phase of HBV or HCV infection;
- A history of immunodeficiency, including HIV seropositive, or other acquired or congenital immunodeficiency diseases;
- Active infection or unexplained fever > 38.5°C within 2 weeks of initial dosing;
- A history of clinically severe cardiovascular disease;
- Abnormal electrocardiogram (ECG) examination;
- Cerebrovascular accident or transient ischemic attack occurred within 6 months before entering the study;
- Have other malignancies within 5 years prior to screening, other than adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery (allowing hormone therapy for non-metastatic prostate cancer or breast cancer), and papillary thyroid cancer;
- The subject has another serious/severe acute or chronic illness or mental illness, including recent (within the past year) or current suicidal ideation or behavior, or laboratory abnormalities that may increase the risks associated with participation in the study or administration of the investigational drug, may interfere with the interpretation of the study results, or may interfere with the investigator's judgment;
- The subjects are the staff of the research center directly related to this clinical trial or their family members, or the subordinates of this trial although not directly related to this trial, or the staff employed by the sponsor directly related to this trial;
- Pregnant and lactating women;
- The subject is unable to swallow, or has a history of active gastrointestinal inflammation, chronic diarrhea, known diverticulosis, or a history of gastrectomy or gastric banding that affects drug absorption;
- The subject is taking a known medium or strong CYP inducer;
- In the judgment of the investigator, objective conditions (including the subject's psychological state, family relationship, social factors or geographical factors) make the subject unable to complete the planned study or the subject has other factors, concomitant diseases, combined treatment or abnormal laboratory examination that may lead to the forced termination of the study.
Quoted from ClinicalTrials.gov, NCT06122389, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06122389, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.